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Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of
tumorigenesis in endometrial cancers, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an
attractive therapeutic approach. In this review, we discuss the biologic and therapeutic eﬀects of HDAC inhibitors (HDACIs) in
treating endometrial cancer. HDACIs were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and the expression
ofgenesrelatedtothemalignantphenotypeinavarietyofendometrialcancercelllines.Furthermore,HDACIswereabletoinduce
the accumulation of acetylated histones in the chromatin of the p21WAF1 gene in human endometrial carcinoma cells. In xenograft
models, some HDACIs have demonstrated antitumor activity with only few side eﬀects. In this review, we discuss the biologic and
therapeutic eﬀects of HDACIs in treating endometrial cancer, with a special focus on preclinical studies.
1.Introduction
Endometrialcanceristheseventhmostcommonmalignancy
among women worldwide. Despite the fact that most cases
are diagnosed at an early stage, the death rate has increased
steadily over the past 20 years. The lack of an eﬀective,
standardized adjuvant treatment for women at a high risk
of recurrence has contributed to these disappointing results
(reviewed in [1]). The most frequent genetic alteration
in type I endometrioid carcinoma is PTEN inactivation
by mutation, followed by microsatellite instability and
mutations of K-ras and β-catenin. In type II cancers, p53
mutation is the most frequent genetic alteration, followed
by inactivation of p16 and e-cadherin and ampliﬁcation of
Her2/neu (reviewed in [1]).
One of the most important mechanisms in chromatin
remodeling is the post-translational modiﬁcation of the N-
terminal tails of histones by acetylation, which contributes to
a “histone code” determining the activity of target genes [2].
Transcriptionally silent chromatin is composed of nucleo-
somes in which the histones have low levels of acetylation on
the lysine residues of their amino-terminal tails. Acetylation
of histone proteins neutralizes the positive charge on lysine
residues and disrupts the nucleosome structure, allowing
unfolding of the associated DNA with subsequent access by
transcriptionfactors,resultinginchangesingeneexpression.
Acetylation of core nucleosomal histones is regulated by the
opposing activities of histone acetyltransferases (HATs) and
histone deacetylases (HDACs). HDACs catalyze the removal
of acetyl groups on the amino-terminal lysine residues of
core nucleosomal histones, and this activity is generally
associated with transcriptional repression. HDACs remove
the acetyl groups which then induce a positive charge on
the histones, and this suppresses gene transcription, includ-
ing tumor suppressor genes silenced in cancer. Moreover,
acetylation of histones facilitates destabilization of DNA-
nucleosome interaction and renders DNA more accessible
to transcription factors [3]. Aberrant recruitment of HDAC
activity has been associated with the development of certain
human cancers [4]. HDAC inhibitors (HDACIs) can inhibit
cancer cell growth in vitro and in vivo, revert oncogene-
transformedcellmorphology,induceapoptosis,andenhance
cell diﬀerentiation.
The classes of HDACIs that have been identiﬁed are: (a)
organic hydroxamic acids (e.g., Trichostatin A (TSA) and
suberoylanilide bishydroxamine (SAHA)) (b) short-chain2 Obstetrics and Gynecology International
Table 1: Overview of frequently used histone deacetylase inhibitors that are available for clinical and research purposes.
Substance groups Derivatives Isotype
Hydroxamates
Trichostatin A (TSA) I, II
Suberoylanilide hydroxamic acid (SAHA, vorinostat) I, II, IV
LBH589 (panobinostat) I, II, IV
PCI24781 (CRA-024781) I, IIb
LAQ824 I, II
PXD101 (belinostat) I, II, IV
ITF2357 I, II
SB939 Unknown
JNJ-16241199 (R306465) I
m-carboxycinnamic acid bishydroxamide (CBHA)
Scriptaid
Oxamﬂatin
Pyroxamide
Cyclic hydroxamic acid containing peptides (CHAPs)
Short chain fatty acids
Butyrate I, IIa
Valproate I, IIa
AN-9
OSU-HDAC42
Benzamides
MS-275 (entinostat) 1, 2, 3, 9
MGCD0103 1, 2, 3, 11
Pimelic diphenylamide 1, 2, 3
M344
N-acetyldinaline (CI-994)
Cyclic tetrapeptides
Apicidine I, II
Trapoxins
HC-toxin
Chlamydocin
Depsipeptide (FR901228 or FK228) (romidepsin) 1, 2, 4, 6
Sulfonamide anilides N-2-aminophenyl-3-[4-(4-methylbenzenesulfonylamino)-phenyl]-2-propenamide
Others
Depudecin
NDH-51
KD5150 Pan-HDACI
Class I: HDAC1, -2, -3 and -8; class IIa: HDAC4, -5, -7, and -9; class IIb: HDAC 6, and -10; class III: SIRT1-7; class IV: HDAC11.
fatty acids (e.g., butyrates and valproic acid (VPA)), (c)
benzamides (e.g., MS-275), (d) cyclic tetrapeptides (e.g.,
trapoxin), and (e) sulfonamide anilides [5] (see Table 1).
In this review, we discuss the biologic and therapeutic
eﬀects of HDACIs in treating endometrial cancer, with a
special focus on preclinical studies.
2. Mechanismof Action
Histone deacetylases (HDACs) comprise a family of 18 genes
that are subdivided into four classes [6]. Classes I, II, and
IV are referred to as “classical” HDACs and are generally
simultaneously targeted by most HDACIs (Table 1). HDACIs
wereinitiallydiscoveredonthebasisoftheirabilitytoreverse
the malignant phenotype of transformed cells in culture. It
has been shown that HDACIs carry the potential to activate
diﬀerentiation programs on one hand, while on the other
hand they were also shown to inhibit cell proliferation by
cell cycle arrest in the G1 and/or G2 phases of the cell
cycle and to induce apoptosis in cultured transformed cells.
p21WAF1 and p27KIP1 are cyclin-dependent kinase inhibitors
(CDKIs) that bind to cyclin-dependent kinase complexes
and decrease kinase activity, and may act as key regulators
of the G0/G1 accumulation (reviewed in [7]). The p21WAF1
expression in particular is induced by HDACIs in various
cell lines. Additionally, this event is associated with both an
increase in histone acetylation in the promoter region of
the p21WAF1 gene and a selective loss of a speciﬁc HDAC
enzyme, HDAC1, in the same region [8]. Therefore, the
upregulation of p21WAF1 is a direct consequence of HDACIs
on p21WAF1 transcription. In the future, testing should be
conducted using p21WAF1-negative cell lines to see if p21WAF1
is absolutely required for HDACI-induced growth arrest.Obstetrics and Gynecology International 3
Takai et al. examined the eﬀect of HDACIs on the expression
of p21WAF1 and p27KIP1 in endometrial cancer cells by
Western blot analysis. HDACIs markedly upregulated the
level of p21WAF1 and p27KIP1 proteins, which were expressed
at negligible levels in the untreated cell lines. Conversely,
HDACIs decreased the levels of cyclin D1 and cyclin D2.
HDACIs decreased the bcl-2 levels. E-cadherin binds to β-
catenin and can act as a tumor suppressor gene; its promoter
has CpG islands which are frequently methylated in selected
cancers. HDACIs markedly increased the expression level
of E-cadherin in endometrial cancer cells and exhibited
antiproliferative activity in these cells [9–14]. HDACIs have
also been shown to generate reactive oxygen species (ROS)
in solid tumor and leukemia cells [15–17], which may
contribute to the mechanism. HDACIs have been shown
to inhibit angiogenesis. HDACIs repress the expression of
proangiogenic factors such as HIF1α,V E G F ,V E G Fr e c e p t o r ,
endothelial nitric oxide synthase, IL-2 and IL-8 and the
induction of antiangiogenic factors, such as p53 and von
Hippel-Lindau (reviewed in [18]). HDACIs should not be
considered to act solely as enzyme inhibitors of HDACs.
A large variety of nonhistone transcription factors and
transcriptional co-regulators are known to be modiﬁed by
acetylation. HDACIs can alter the degree of acetylation non-
histoneeﬀectormoleculesandtherebyincreaseorrepressthe
transcription of genes by this mechanism. Examples include:
ACTR, cMyb, E2F1, EKLF, FEN 1, GATA, HNF-4, HSP90,
Ku70, NFκB, PCNA, p53, RB, Runx, SF1 Sp3, STAT, TFIIE,
TCF, YY1, and so forth, (reviewed in [18]).
3. Overview andPreclinicalStudies of HDACIs
A variety of structurally distinct classes of compounds
that inhibit deacetylation of both histone and non-histone
proteins have gradually been identiﬁed (Table 1). Despite the
shared capacity of each class of HDACIs to promote histone
acetylation, individual HDACIs exert diﬀerent actions on
signal transduction and the induction of diﬀerentiation
and/or apoptosis. Table 2 shows data from diﬀerent reports
investigating endometrial cancer cell lines treated with
diﬀerent classes of HDACIs. Many of the in vitro studies use
the Ishikawa cell line. Nishida. succeeded in establishing of
a well-diﬀerentiated endometrial adenocarcinoma cell line,
Ishikawa cells, from a 39-year old Japanese patient more
t h a n2 0y e a r sa g o[ 19]. Because this cell line bears estrogen
and progesterone receptors, the cells have been used in
numerous basic research areas such as reproductive biology
and molecular science.
3.1. Trichostatin A (TSA). The trichostatins were initially
isolated from Streptomyces hygroscopicus as antifungal
antibiotics in 1976 [20, 21]. About 10 years later, TSA and
its analogues were discovered to induce cell diﬀerentiation of
murineerythroleukemiacellsandtoinducehyperacetylation
of histone proteins at nanomolar concentrations. TSA has
been extensively studied; it has antitumor activity and can
induce diﬀerentiation of some cancer cell lines, but its
Table 2: Data investigating endometrial cancer cell lines treated
with diﬀerent classes of HDACIs.
HDACI Cell line ED50 (M)
TSA
Ishikawa 5.2 × 10−8
HEC-1B 5.1 × 10−8
HEC59 7.0 × 10−8
RL95-2 9.8 ×10−8
KLE 7.2 ×10−8
AN3CA 1.9 ×10−8
Ark2 2.5 ×10−8
SAHA
Ishikawa 7.8 × 10−7
HEC-1B 7.8 × 10−7
HEC59 1.2 × 10−6
RL95-2 2.4 ×10−6
KLE 2.5 ×10−6
AN3CA 3.1 ×10−6
CBHA
Ishikawa 1.8 × 10−6
HHUA 2.5 × 10−6
HEC-1B 2.2 × 10−6
Scriptaid Ishikawa 9.0 × 10−6
NaB
Ishikawa 8.3 × 10−4
HEC-1B 8.4 × 10−4
HEC59 1.8 × 10−3
RL95-2 3.0 ×10−3
KLE 3.9 ×10−3
AN3CA 4.1×10−3
VPA
Ishikawa 7.0 × 10−4
HEC-1B 7.5 × 10−4
HEC59 8.2 × 10−4
RL95-2 2.5 ×10−3
KLE 2.3 ×10−3
AN3CA 3.8 ×10−3
MS-275
Ishikawa 9.7 × 10−7
HEC-1B 2.2 × 10−6
RL95-2 1.0 × 10−6
HHUA 7.8 ×10−7
AN3CA 5.0 × 10−7
Ark2 5.0 ×10−7
M344 Ishikawa 2.3 × 10−6
Apicidine Ishikawa 1.0 × 10−6
PsA Ishikawa 7.5 × 10−6
Oxamﬂatin
Ishikawa 2.5 × 10−7
AN3CA 2.5 × 10−7
Ark2 2.5 × 10−7
clinical utility has been restricted because of toxic side-
eﬀects in vivo [22]. TSA causes mitotic arrest through
the formation of aberrant mitotic spindles, probably by
interferingwithchromosomeattachment,butdoesnotaﬀect
mitotic microtubules [22]. This eﬀect may account for the
higher cytotoxicity of TSA in comparison to other HDACIs4 Obstetrics and Gynecology International
(i.e., suberoylanilide bishydroxamine). HDAC inhibition is
not believed to have a generalized eﬀect on the genome, but
only on the transcription of a small subset of the genome.
Diﬀerential display analysis of transformed lymphoid cell
lines revealed that the expression of only 2%–5% of tran-
scribed genes is changed signiﬁcantly after treatment with
TSA [23]. The eﬀective dose of TSA that inhibited 50%
clonal growth (ED50) of the endometrial cancer cell lines
(Ishikawa, HEC-1B, HEC59, RL95-2, KLE, and AN3CA)
was calculated, and ranged between 5.1 × 10−8 Ma n d1 . 9
× 10−7 M[ 9]( Table 2). Dowdy et al. demonstrated that
combined treatment with TSA and paclitaxel caused syner-
gistic inhibition of cell growth of Ark2 and KLE endometrial
cancer cells [24]. These eﬀects were conﬁrmed in a mouse
xenograft model. Treatment with TSA and paclitaxel led to
a signiﬁcant increase in acetylated tubulin and microtubule
stabilization. This study provides the evidence of nonhistone
protein acetylation as one possible mechanism by which
HDACIs reduce cancer growth.
3.2. Suberoylanilide Bishydroxamine (SAHA, Vorinostat).
Hydroxamic acid type inhibitors make up the largest and
broadest group of HDACIs described to date. The inhibition
of HDACs by SAHA occurs through a direct interaction
with the catalytic site of the enzyme, as shown by X-ray
crystallography studies [25]. Among the synthetic HDACIs,
SAHAisthemostadvancedcandidateasacancertherapeutic
drug, and is under phase I and II clinical trials [26, 27].
SAHA has signiﬁcant antitumor activity against many tumor
types at dosages that can be tolerated by patients when
administered intravenally and orally [28]. Some HDACIs
(e.g., TSA and trapoxin) are of limited therapeutic use due
to poor bioavailability in vivo and have toxic side eﬀects at
high doses. SAHA, however, is relatively safe and non-toxic
invivo.TheeﬀectivedoseofSAHAthatinhibited50%clonal
growth(ED50)oftheendometrialcancercelllines(Ishikawa,
HEC-1B, HEC59, RL95-2, KLE, and AN3CA) was calculated
and ranged between 7.8 × 10−7 Ma n d3 . 1× 10−6 M[ 9]
(Table 2).
3.3. m-carboxycinnamic Acid Bishydroxamide (CBHA).
CBHA is a member of a recently synthesized family of hybrid
polar compounds that have been shown to be inhibitors of
HDAC [29] and potent inducers of transformed cell growth
arrest and terminal diﬀerentiation at micromolar (LD50
range, 1–4μM) concentrations [30]. The eﬀective dose of
CBHA that inhibited 50% clonal growth (ED50) of the
endometrial cancer cell lines (Ishikawa, HEC-1B, HHUA)
was calculated and ranged between 1.8 × 10−6 Ma n d2 . 5×
10−6 M for CBHA [10]( Table 2). On the other hand, normal
endometrial epithelial cells were viable after treatment with
the same doses of CBHA that induced growth inhibition of
endometrial cancer cells [10].
3.4. Scriptaid. Using a high-throughput system based on a
stably integrated transcriptional reporter to screen a library
of 16,320 compounds (DIVERset, Chembridge, San Diego,
CA), Su et al. identiﬁed a novel HDACI, termed Scriptaid
[31]. Nullscript, which possesses a shorter side-chain (3C)
than Scriptaid (5C) between the tricyclic core and the
carbonyl group, was inactive in transcriptional facilitation.
This conﬁrms that the linker chain has to be a certain length
for HDAC inhibition to occur. Scriptaid has a common
structure with TSA and SAHA, that is, a hydroxamic acid
zinc-binding group linked via a spacer (5 or 6 CH2)
to a hydrophobic group [31]. Using an immunoblotting
assay of histone deacetylation, Su et al. demonstrated that
Scriptaid is a potent HDACI with a >100-fold increase
in histone acetylation, with relatively low toxicity [31].
Scriptaid conferred the greatest eﬀect on augmentation of
the signal transduction TGFβ pathway, including a number
of human suppressor genes such as SMAD4 [31]. The eﬀect
of Scriptaid in human cancers, however, has not been fully
examined. A recent study by Keen et al. indicated that
Scriptaid had a signiﬁcant growth-suppressing eﬀect on ER-
negative human breast cancer cells [32]. The eﬀective dose
of Scriptaid that inhibited 50% clonal growth (ED50) of
the Ishikawa endometrial cancer cell line was calculated at
9.0 × 10−6 M[ 11]( Table 2). On the other hand, normal
endometrial epithelial cells were viable after treatment with
the same doses of Scriptaid that induced growth inhibition
of endometrial cancer cells [11].
3.5. Sodium Butyrate (NaB). It was ﬁrst reported in 1978
that millimolar concentrations of sodium butyrate (NaB)
inhibited HDACs in vitro [33]. NaB is normally present in
the human colon as a product of the metabolic degradation
of complex carbohydrates by colonic bacteria and regulates
the physiological diﬀerentiation of colonocytes, suggesting
its possible use in the prevention of colorectal cancer and the
treatment of premalignant and neoplastic lesions. Butyrate
and its derivatives have a long history of safe clinical
use in the treatment of inherited and acquired metabolic
disorders. Some studies suggest that many of the cellular
activities of phenylbutyrate are more dependent on its
butyricacidcomponentthanitsphenylgroup.Arecentstudy
by Terao et al. indicated that NaB had a signiﬁcant growth-
suppressingeﬀectonhumanendometrialandovariancancer
cells irrespective of their p53 gene status [34]. NaB, a
low-potency HDACI, has been extensively studied; it has
antitumor activity and can induce diﬀerentiation of some
cancer cell lines, but its clinical utility has been restricted
by its short half-life (5 minutes), limiting the ability to
achieve a therapeutic plasma level. NaB and phenylbutyrate
are degraded rapidly after i.v. administration and therefore
require high doses exceeding 400 mg/kg/day [35]. Further-
more, these compounds are not speciﬁc for HDACs as they
also inhibit phosphorylation and methylation of proteins as
well as DNA methylation [35]. The eﬀective dose of NaB
that inhibited 50% clonal growth (ED50) of the endometrial
cancer cell lines (Ishikawa, HEC-1B, HEC59, RL95-2, KLE,
and AN3CA) has been calculated and ranged between 8.3 ×
10−4 Ma n d4 . 1× 10−3 Mf o rN a B[ 9]( Table 2).
3.6. Valproic Acid (VPA). Valproic acid, a shortchain fatty
acid, has been approved for clinical use in the treatment of
epilepsy and is frequently used in clinical trials and for inObstetrics and Gynecology International 5
vitro research based on its HDAC inhibitory eﬀect at com-
paratively high (millimolar) concentrations [36]. Valproic
acid has also been identiﬁed as an antiproliferative agent and
HDACI [37]. Some HDACIs (e.g., TSA and trapoxin) are of
limited therapeutic use due to poor bioavailability in vivo as
well as toxic side eﬀects at high doses, but VPA is relatively
safe and non-toxic in vivo. The eﬀective dose of VPA that
inhibited 50% clonal growth (ED50) of the endometrial
cancer cell lines (Ishikawa, HEC-1B, HEC59, RL95-2, KLE,
and AN3CA) has been calculated and ranged between 7.0 ×
10−4 Ma n d3 . 8× 10−3 M[ 9]( Table 2).
A previous study tested the ability of VPA to inhibit
the growth of human HEC-1B endometrial cancer tumors
growing in immunodeﬁcient mice [9]. Administration of
VPA remarkably suppressed the growth of the tumors (P
<.01). No signiﬁcant diﬀerences in either the mean weights,
histologyoftheinternalorgans,andmeanbloodchemistries,
including liver parameters and hematopoietic values, were
foundbetweendiluent-treatedmiceandthosethatreceived5
weeks of therapy. These tumors were sampled for the expres-
sion of p21WAF1 using immunohistochemistry on formalin-
ﬁxedparaﬃn-embeddedsections.HEC-1Bendometrialcan-
cer cells treated with VPA showed strong nuclear staining.
Control cancer cells from untreated mice had negative or
focal weak staining for p21WAF1. This in vivo study shows
that VPA at 0.3–1.5mM inhibited cell proliferation, induced
cell cycle arrest and stimulated apoptosis in endometrial
cancer cells. This range of concentrations of VPA can be
achieved in a patient’s serum when that patient is receiving
a daily dose of 20–30mg/kg for epilepsy. These data are
also consistent with the in vitro data. This anticancer
activity occurred without any major side-eﬀects, raising
hopesthatVPAmaybecomeausefultherapyforendometrial
cancers. Furthermore, VPA has convenient pharmacokinetic
properties with a signiﬁcantly longer biological half-life than
the other HDACIs [38].
3.7. MS-275 (Entinostat). MS-275 (MS-27-275) is a syn-
thetic novel benzamide which exerts HDAC inhibitory activ-
ity and also induces the expression of the cyclin-dependent
kinase inhibitor p21WAF1 and gelsolin, and changes the cell
cycle distribution [38, 39]. MS-275 has shown antiprolifer-
ative activity in various in vitro and in vivo human tumor
models [40, 41], and is currently being tested in clinical trials
involving patients with solid tumors or hematological malig-
nancies [42]. The eﬀective dose of MS-275 that inhibited
50% clonal growth (ED50) of the endometrial cancer cell
lines(Ishikawa,HHUA,HEC-1BandRL95-2)wascalculated
and ranged between 7.8 × 10−7 Ma n d2 . 2× 10−6 M[ 12]
(Table 2). On the other hand, normal endometrial epithelial
cells were viable after the treatment with the same doses
of MS-275 that induced growth inhibition of endometrial
cancer cells [12]. Jiang et al. reported that over the course of
4 days, there was a 60% reduction in the serous endometrial
cancercelllineArk2cellcountsbyMS-275(whichtheycalled
HDAC-I1) (0.5 μM) treatments, as compared to controls
treated with DMSO solvent (Table 2). They reported growth
inhibition of both endometrioid (Ishikawa and AN3) and
serous (Ark2) endometrial carcinomas [43].
3.8. M344. Synthetic amide analogs were discovered to have
a common structure with TSA [44]. Using an in vitro
enzyme inhibition assay of histone deacetylation, Jung et
al. demonstrated that M344 is a potent HDACI and an
inducer of terminal cell diﬀerentiation [44]. The eﬀective
dose of M344 that inhibited 50% clonal growth (ED50) of
the Ishikawa endometrial cancer cell line was calculated at
2.3 × 10−6 M[ 13]( Table 2). On the other hand, normal
endometrial epithelial cells were viable after the treatment
with the same doses of M344 that induced growth inhibition
of endometrial cancer cells [13].
3.9. Apicidin. Cyclic peptide HDACIs can be further divided
into two classes: those with an epoxyketone group such as
HC-toxin and trapoxin, and those without such a group
(apicidin, depsipeptide or FK228). Apicidin is a novel cyclic
tetrapeptide with a potent broad spectrum of antiprotozoal
activity against Apicomplexan parasites [45]. Its structure is
related to trapoxin, a potent HDACI, and some biological
activity, including antiproliferative and toxic eﬀects, have
been shown in some cancer cell lines [46]. The eﬀective
dose of apicidin that inhibited 50% clonal growth (ED50)
of the Ishikawa endometrial cancer cell lines was calculated
at 1.0 × 10−6 M[ 14]( Table 2). On the other hand, normal
endometrial epithelial cells were viable after the treatment
with the same doses of HDACIs that induced growth
inhibition of endometrial cancer cells [14]. Ueda et al.
[14] and Ahn et al. [47] independently demonstrated that
apicidin has antitumor properties on Ishikawa endometrial
cancer cells by selectively inducing the genes related to cell
cycle arrest and apoptosis.
3.10. Psammaplin A. Psammaplin A (PsA) is a natural
bromotyrosine derivative from a two-sponge association,
Poecillastra sp.a n dJaspis sp., which was ﬁrst isolated from
the Psammaplysilla sponge [45]. It was reported that PsA
has antibacterial and antitumor properties, and also inhibits
various enzymes including topoisomerase II, farnesyl pro-
tein transferase, leucine amino peptidase, and chitinase
(reviewed in [48]). Recently, it was reported that PsA
inhibits both HDAC and DNA methyltransferase (DNMT)
as epigenetic modiﬁers of the tumor suppressor gene [49].
PsA caused antiproliferative activity and induced cell cycle
arrest or apoptosis in Ishikawa human endometrial cancer
cells. PsA inhibited the proliferation of Ishikawa cells in a
dose-dependent manner. The 50% inhibitory concentration
(IC50) of PsA was found to be 5μg/mL (7.5 × 10−6 M) after
48 h treatment(Table 2). PsA increased the proportion in the
G1 phase and G2/M phases of the cell cycle [48].
3.11. Oxamﬂatin. Oxamﬂatin is an aromatic sulfonamide
derivative with a hydroxamic acid group that was identiﬁed
asacompoundinducingthemorphologicalreversionofv-K-
ras-transformed NIH3T3 cells from a chemical library [50].
In addition, the morphology of NIH3T3 cells transformed
by various other oncogenes such as v-sis,v - src,M E K EE or v-
fos was also reverted by oxamﬂatin. Kim et al. analysed the
eﬀect of oxamﬂatin on the proliferation of eight mouse and6 Obstetrics and Gynecology International
human tumor cell lines. The 50% inhibitory concentrations
ofoxamﬂatinforallthecelllinesexceptCCD-19Lu,anormal
h u m a nl u n gc e l ll i n e ,w e r eb e l o w0 . 7 2μg/mL, while that for
CCD-19Lu was 1.4μg/mL [51]. Over the course of 4 days,
there was a 78% reduction in the serous endometrial cancer
celllineArk2cellcountsbyoxamﬂatin(0.25μM)treatments,
as compared to controls treated with DMSO solvent. The
most striking observation is the 95% reduction in cell counts
following the administration of 0.75μM oxamﬂatin to Ark2
cells [43]. This report resulted in growth inhibition of
both endometrioid (Ishikawa and AN3) and serous (Ark2)
endometrial carcinomas.
4. Conclusions
In this review, we summarize recent preclinical studies on
the use of HDACIs, especially in human endometrial cancer
cells. Many questions are currently still unanswered with
respect to HDACI speciﬁcities for deﬁnite tumor subtypes
and the molecular mechanisms underlying HDACI-induced
diﬀerentiation, cell cycle arrest and apoptosis. In addition,
the regulation mechanisms of the speciﬁc gene expression
and recruitment of HDAC complex to the speciﬁc promoter
sites remain still to be determined. Also, it is still unclear to
whatextentdiﬀerentHDACsexhibitdiﬀerentandpotentially
overlapping functions, and it is important to distinguish the
HDACspeciﬁcityofHDACIsforthedevelopmentofselective
therapy on the molecular level. Further work is needed to
improve our understanding of why transformed cells are
more susceptible to the eﬀect of HDACIs than normal cells.
Also,combinationsofHDACIswithdiﬀerentiation-inducing
agents, with cytotoxic agents, and even with gene therapy
may represent novel therapeutic strategies and new hope for
the treatment of endometrial cancer.
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